NCT06031844View on ClinicalTrials.gov

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 16, 2023

Primary Completion Date

December 17, 2024

Study Completion Date

December 23, 2024

Conditions
Coronary Heart Disease
Interventions
DRUG

DFV890

oral film-coated tablets

DRUG

Placebo

oral film-coated tablets

Trial Locations (7)

27410

Triad Clinical Trials LLC, Greensboro

32209

UF Health Science Center, Jacksonville

33434

Excel Medical Clinical Trials LLC, Boca Raton

57701

Monument Health Clinical Research, Rapid City

91325

Valley Clinical Trials, Northridge

98405

Universal Research Group LLC, Tacoma

H1T 1C8

Novartis Investigative Site, Montreal

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY